Form D · Pharmaceuticals
Lattice Biotech, LLC
Athens, OH · CIK 0001667964
Offering snapshot reported Feb 28, 2017 · SEC filing
- Reported sold
- $512K Offering amount: $8M
- Investors reported
- 25 Form D · investor count
- Minimum accepted
- $5K Reported outside-investor minimum
- First sale
- Jun 8, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
- Reported investors0 → 25
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 28, 2017 | Amendment | $512,000 | No comparison | 25 | SEC filing |
| Feb 29, 2016 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 04
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-258271
Source: Form D, filed Feb 28, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Nick Henderson | Executive |
| Joseph Deslar Kittle | Executive |
| Noel Douglas Martin | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
340 West State Street, Suite 212
Athens, OH, 45701
Athens, OH, 45701